An international multicentre study of consecutively diagnosed patients with ALCL: outcomes following first-line therapy in routine clinical practice

Nicolas Martinez-Calle, Amy A Kirkwood, Maxine Lamb, Alexandra Gwen Smith, Kate Manos, Caroline Shrubsole, N Gray, Sapna Ladani, K Lewis, Mark Bishton, Matthew J Ahearne, Eliza Hawkes, Wendy Osborne, G Colins, C. Burton, Christopher P Fox

Research output: Contribution to journalMeeting abstractpeer-review


Standard first-line (1L) therapy for systemic ALCL (sALCL) is CHOP-based chemotherapy, with or without consolidative autologous stem cell transplant (ASCT) (Schmitz, Blood, 2010). Approximately 40–65% of patients experience relapsed/refractory disease, for which brentuximab vedotin (BV) as monotherapy has established efficacy (Pro, Blood, 2017)

BV is currenty FDA-aproved in combination with CHP (CHP+A) as first-line treatment for CD30 + PTCL, based E2 results (34% reduction in risk of death), an effect only demonstrable in ALCL (70% of E2 cohort) (Horwitz, Lancet, 2019). We investigated outcomes of unselected ALCL patients treated in routine practice prior to widespread approval of BV in 1L.
Original languageEnglish
Article numberBSH2020-PO-091
JournalBritish Journal of Haematology
Issue numberS1
Publication statusPublished - 27 Apr 2020
Event60th Annual Scientific Meeting of the British Society for Haematology - Birmingham, United Kingdom
Duration: 27 Apr 202029 Apr 2020
Conference number: 60

Cite this